dulaglutide vs tirzepatide π‘ New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that was noninferior to for major cardiovascular events (12.2% 13.1%; HR 0.92). What tirzepatide cardiovascular outcomes An Observational
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 7 - Aug 12





:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)




















